Antidiabetic Agents in the Management of Hepatic Fibrosis in Type 2 Diabetes Mellitus and MASLD/MASH: A Narrative Review
This article aims to review antidiabetic agents with evidence supporting hepatic fibrosis reduction, as well as those lacking such evidence.